Cellectis (NASDAQ:CLLS) Posts Earnings Results, Beats Estimates By $0.11 EPS

Cellectis (NASDAQ:CLLS) announced its earnings results on Friday. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.11, Zacks reports. Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. The firm had revenue of $37.16 million for the quarter, compared to the consensus estimate of $8.22 million.

Cellectis Stock Performance

Shares of Cellectis stock traded up $0.06 on Friday, hitting $3.19. The stock had a trading volume of 77,515 shares, compared to its average volume of 202,495. The stock has a market cap of $177.30 million, a price-to-earnings ratio of -3.89 and a beta of 3.11. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.58. Cellectis has a 52-week low of $1.10 and a 52-week high of $5.48. The company’s 50 day moving average price is $3.39 and its 200 day moving average price is $2.42.

Institutional Investors Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Cellectis S.A. (NASDAQ:CLLS) by 228.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,722,664 shares of the biotechnology company’s stock after purchasing an additional 3,284,409 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 8.50% of Cellectis worth $5,856,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CLLS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, October 8th. Wells Fargo & Company restated a “positive” rating and set a $4.00 price target on shares of Cellectis in a report on Monday, October 20th. Barclays increased their price target on Cellectis from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Finally, Wall Street Zen raised Cellectis to a “hold” rating in a research report on Saturday, September 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cellectis has an average rating of “Hold” and an average target price of $6.00.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.